Gilead Sciences Inc
GILD
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
17,600
Gilead Sciences Inc News & Analysis
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
10 cheap US dividend-growth stocks to buy
The stocks of these companies with a history of dividend increases look undervalued today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,149.30 | 6.90 | -0.08% |
| CAC 40 | 8,179.50 | 1.67 | -0.02% |
| DAX 40 | 24,780.79 | 16.73 | -0.07% |
| Dow JONES (US) | 49,209.79 | 197.87 | -0.40% |
| FTSE 100 | 10,314.59 | 26.97 | -0.26% |
| HKSE | 26,834.77 | 59.20 | 0.22% |
| NASDAQ | 23,195.00 | 397.11 | -1.68% |
| Nikkei 225 | 54,720.66 | 2,065.48 | 3.92% |
| NZX 50 Index | 13,421.52 | 9.08 | 0.07% |
| S&P 500 | 6,908.31 | 68.13 | -0.98% |
| S&P/ASX 200 | 8,857.10 | 9.20 | -0.10% |
| SSE Composite Index | 4,067.74 | 51.99 | 1.29% |